Document:

EX-4.17

 Exhibit 4.17 

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE
SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL
APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. THERE IS NO AND THERE IS NOT EXPECTED TO BE A PUBLIC MARKET FOR THE SHARES OF COMMON STOCK ISSUABLE UPON ANY EXERCISE HEREOF. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE
FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
 WARRANT TO PURCHASE 

SHARES OF COMMON STOCK OF 

AMEDICA CORPORATION 
  

			
	Warrant No.                     	 	Issue Date:                     , 2013

 This certifies that, for value received,
                    (the “Holder”), is entitled to purchase from Amedica Corporation, a Delaware corporation with offices at 1885
West 2100 South, Salt Lake City, UT 84119 (the “Company”),             (                )
shares of the Company’s common stock, $0.01 par value per share (“Common Stock”), as such number and class of securities may be adjusted in accordance with the terms of Section 4 below, for the Stated Purchase Price
(defined below), at any time up to and including 5:00 p.m. (New York City time) on the Warrant Expiration Date (as defined below) in accordance with the terms hereof. “Stated Purchase Price” shall mean the purchase price to be paid
upon exercise of this Warrant in accordance with the terms hereof, which price initially shall be $1.00 per share of Common Stock. The Stated Purchase Price shall be subject to adjustment from time to time pursuant to the provisions of
Section 4 below. “Warrant Expiration Date” means 5:00 p.m., New York City time, on the fifth anniversary of the original date of issuance of the Warrant. If pursuant to the above the Warrant Expiration Date would be a Saturday,
Sunday or legal holiday in the State of Utah, then the Warrant Expiration Date shall be the next succeeding date that is not a Saturday, Sunday or legal holiday. 

1. Exercise. 
 (a)
Manner of Exercise. This Warrant may be exercised at any time or from time to time for all or any part of the number of shares of Common Stock (or other securities) then purchasable upon its exercise (the “Shares”); provided,
however, that this Warrant shall be void and all rights represented hereby shall cease unless exercised before the end of the Warrant Expiration Date. In order to exercise this Warrant, in whole or in part, Holder will deliver to the Company at its
principal executive offices, or at such other office as the Company may designate by notice in writing, (i) this Warrant, (ii) a written notice of Holder’s election to exercise this Warrant substantially in the form of Exhibit
A attached hereto (the “Notice of Exercise”), and 

 (iii) any documents required pursuant to Section 7 hereof, and shall pay to the Company in cash, by a
certified or cashier’s check drawn on a United States Bank made payable to the order of the Company, or by wire transfer of funds to a bank account designated by the Company, an amount equal to the aggregate Stated Purchase Price for all Shares
as to which this Warrant is exercised. 
 (b) Net Exercise. 

(1) In lieu of exercising this Warrant by payment in cash, or by check or wire transfer, the Holder may elect to receive Shares equal to the
value of this Warrant (or the portion thereof being exercised), at any time after the date hereof and before the end of the Warrant Expiration Date, by surrender of this Warrant at the principal executive office of the Company, together with the
Notice of Exercise in the form annexed hereto, in which event the Company will issue to the Holder a number of Shares computed in accordance with the following formula: 
  

					
	X	 	=	 	Y × (A-B)
		 		 	      A

  

											
	 Where,
	 	 	X	  	 	 	=	  	  	the number of Shares to be issued to Holder pursuant to this net exercise;
				
		 	 	Y	  	 	 	=	  	  	the number of Shares for which the net exercise election is made;
				
		 	 	A	  	 	 	=	  	  	the fair market value of one Share at the time the net exercise election is made; and
				
		 	 	B	  	 	 	=	  	  	the Stated Purchase Price (as adjusted at the date of the net exercise election is made).

 (2) For purposes of this Section 1(b), the fair market value of a Share and the effectiveness of the
exercise of this Warrant are determined as follows: 
 (i) if the exercise is in connection with an initial public offering, and if the
Company’s registration statement relating to such offering has been declared effective by the Securities and Exchange Commission, then the fair market value shall be the initial “Price to Public” specified in the final prospectus with
respect to the offering (net of applicable underwriting commissions), and such exercise shall be effected upon the date of such initial public offering, subject to due, proper and prior surrender of this Warrant and the closing of the initial public
offering; 
 (ii) if the exercise is in connection with a Change of Control, then the fair market value shall be the value received by the
holders of Shares pursuant to the Change of Control for each share of such securities, and the exercise shall be effective upon the closing of such Change of Control, subject to due, proper and prior surrender of this Warrant and the closing of the
Change of Control; or 
 (iii) if the exercise is other than in connection with subsections (i) or (ii) above and the Shares
are traded on a securities exchange or through the Nasdaq Global Market, the value shall be deemed to be the average of the closing prices of the securities on such exchange over the thirty (30) day period ending three (3) days prior to
the net exercise election; or 

  
 -2- 

 (iv) if the exercise is other than in connection with subsections (i) or
(ii) above and the Shares are traded over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty (30) day period ending three (3) days prior to the net
exercise; or 
 (v) if the exercise is other than in connection with subsections (i) or (ii) above and the Shares are not traded
on the over-the-counter market or on an exchange, the fair market value shall be determined in good faith by the Company’s Board of Directors (the “Board”). 

For purposes of this Warrant, A “Change of Control” shall mean any acquisition of capital stock of the Company, directly or indirectly, any merger,
tender offer, recapitalization or asset sale pursuant to which the Company’s stockholders immediately prior to such transaction hold less than 50% of the voting securities of the surviving corporation immediately after such transaction or the
majority of the assets of the Company are transferred or sold, except that any internal restructuring or re-organization of the Company that does not change the effective ultimate ownership of the Company shall not be deemed a Change of Control.

 (c) Issuance of Shares. Upon receipt of the documents and payments described in Section 1(a), the Company shall, as promptly
as practicable, execute or cause to be executed, and deliver to Holder a certificate or certificates representing the aggregate number of full Shares issuable upon such exercise, together with an amount in cash in lieu of any fraction of a Share, as
hereinafter provided. If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of said certificate or certificates, deliver to the Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased
Shares, which new Warrant shall in all other respects be identical with this Warrant. 
 2. Reservation of Shares. The Company
covenants that it will at all times until the Warrant Expiration Date reserve and keep available out of its authorized and unissued Common Stock (or other securities of the Company, as applicable), solely for the purpose of issue upon exercise of
this Warrant such number of shares of Common Stock (or other securities of the Company, as applicable) as shall then be issuable upon the exercise of this Warrant. 

3. Loss or Mutilation. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant (including a reasonably detailed affidavit with respect to the circumstances of any loss, theft or destruction of such Warrant), and, in the case of any such mutilation, upon surrender and cancellation of this Warrant, the Company, at
Holder’s expense, will execute and deliver, in lieu hereof, a new Warrant of like tenor. 
 4. Adjustments to Shares and Stated
Purchase Price. 
 (a) If the Company at any time after the date hereof through the Warrant Expiration Date subdivides (by any stock
split, stock dividend, recapitalization or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Stated Purchase Price 

  
 -3- 

 
in effect immediately prior to such subdivision will be proportionately reduced and the number of shares issuable upon exercise of this Warrant will be proportionately increased, and if the
Company at any time combines (by reverse stock split, recapitalization or otherwise) its outstanding shares of Common Stock into a smaller number of shares, the Stated Purchase Price in effect immediately prior to such combination will be
proportionately increased and the number of shares issuable upon exercise of this Warrant will be proportionately decreased. If the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise,
change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, subdivision or other
change. 
 (b) When any adjustment is required to be made in the number or kind of Shares purchasable upon exercise of this Warrant, or the
Stated Purchase Price, the Company shall promptly notify the Holder in writing of such event, of the number and description of Shares thereafter purchasable upon exercise of this Warrant, and of the revised Stated Purchase Price. 

5. Fractional Shares. No fractional Shares shall be issued upon the exercise of this Warrant, but, instead of any fraction of a Share
which would otherwise be issuable, the Company shall pay a cash adjustment in respect of such fraction in an amount equal to the same fraction of the fair market value per share of Common Stock (or other securities, as applicable) as of the close of
business on the date of the notice required by Section 1 above, determined in good faith by the Board. 
 6. Warrant Not
Transferable. This Warrant is only exercisable by Holder and it is not transferable to any other party. 
 7. Agreements. As a
condition precedent to any exercise of this Warrant, Holder understands and agrees that it may be required to execute certain documents and agreements (in Company standard form) relating to the purchase and sale of Shares, as well as right of first
refusal, co-sale and voting rights agreements, if applicable, which all other purchasers of the same class of shares are required to execute. Upon the execution and delivery of such documents and agreements, Holder will become a party to, and bound
by, such agreements, as so amended or restated, as to the securities acquired upon exercise of this Warrant. 
 8. Holder’s
Representations and Warranties. Holder, by acceptance hereof, hereby represents as follows: 
 (a) Investment Purpose. The right
to acquire Shares (and the Shares) issuable upon exercise of the Holder’s rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of
selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 

  
 -4- 

 (b) Private Issue. The Holder understands (i) that the Shares issuable upon exercise
of this Warrant are not registered under the Securities Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations of Holder herein. 
 (c)
Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 

(d) Risk of No Registration. The Holder understands that if the Company does not register pursuant to Section 12 of the Securities
Exchange Act of 1934, as amended (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Securities Act is not in effect when it desires to
sell the securities issuable upon exercise of this Warrant, it may be required to hold such securities for an indefinite period. The Holder also understands that any sale of securities issued or issuable hereunder which might be made by it in
reliance upon Rule 144 under the Securities Act may be made only in accordance with the terms and conditions of that Rule. 
 (e)
Accredited Investor. Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D, promulgated under the Securities Act, as presently in effect. 

9. Company’s Representations and Warranties. The Company hereby represents and warrants to Holder as follows: 

(a) Due Authorization. This Warrant has been duly authorized, executed and delivered by the Company and constitutes the valid and
binding obligation of the Company, enforceable in accordance with its terms. 
 (b) Status of Shares; Price. The Shares purchased by
Holder upon any exercise of this Warrant in accordance with its terms will be, when issued by the Company, duly authorized, validly issued, fully paid in compliance with applicable securities laws (assuming the accuracy of the Holder’s
representations and warranties herein) and nonassessable. 
 10. Holder Not Deemed Stockholder. Holder will not, as such, be entitled
to vote or to receive dividends or be deemed the holder Shares that may at any time be issuable upon exercise of this Warrant for any purpose whatsoever, nor shall anything contained herein be construed to confer upon Holder, as such, any of the
rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights, until Holder shall have exercised this
Warrant and been issued Shares in accordance with the provisions hereof. Subject to applicable law, any right not specifically granted hereunder to Holder is hereby disclaimed by the Company. 

11. Modification of Warrant. This Warrant shall not be modified, supplemented or altered in any respect except with the consent in
writing of the Holder and the Company. 

  
 -5- 

 12. Notices. All demands, notices and communications relating to this Warrant shall be in
writing and (i) sent by registered or certified mail, postage prepaid, return receipt requested, (ii) hand delivered, (iii) sent by express mail or other reasonable overnight delivery service, or (iv) sent by telecopy, as follows
(or to such other address as to which notice may be given hereunder by the party entitled to receipt of notice): 
  

			
	If to the Company:
	
	 Amedica Corporation
 1885 West 2100
South

	Salt Lake City, UT 84119
	Attention:	  	Eric K. Olson
		  	Chief Executive Officer
	Telephone:	  	(801) 839-3500
	Telecopy:	  	(801) 839-3605

 13. Governing Law. This Warrant shall be governed by, and construed in accordance with, the laws of the
State of Delaware, without regard to conflict of law principles. 
 14. Jurisdiction. Each of the Company and the Holder hereby
irrevocably submits to the jurisdiction of any Utah State or Federal court sitting in Salt Lake City in any action or proceeding arising out of or relating to this Warrant, and each of the Company and the Holder hereby irrevocably agrees that all
claims in respect of such action or proceeding may be heard and determined in such Utah State court or in such Federal court. Each of the Company and the Holder hereby irrevocably waives, to the fullest extent permitted under applicable law, the
defense of an inconvenient forum to the maintenance of such action or proceeding. Each of the Company and the Holder irrevocably consents, to the fullest extent permitted under applicable law, to the service of any summons and complaint and any
other process by the mailing of copies of such process to them at their respective address specified in Section 12 hereof. Each of the Company and the Holder hereby agrees, to the fullest extent permitted under applicable law, that a final
judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

15. Waiver of Jury Trial. TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE LAW, EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS WARRANT. 

16. Miscellaneous. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the
terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 

[signature page follows] 

  
 -6- 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Shares of Common Stock to be
duly executed as of             , 2013. 
  

			
	AMEDICA CORPORATION
		
	By:	 	  

	Name:	 	Eric K. Olson
	Title:	 	Chief Executive Officer

  
 -7- 

 EXHIBIT A 

EXERCISE FORM 
 (To be
signed only on exercise of Warrant) 
 Amedica Corporation, 

1885 West 2100 South 
 Salt Lake City, UT 84119 

The undersigned hereby irrevocably elects to exercise the right to purchase represented by the within Warrant for, and to purchase thereunder,
                 shares of the stock provided for therein, and requests that certificates for such shares be issued in its name, and, if said number of shares shall not
be all the shares purchasable thereunder, that a new Warrant for the balance remaining of the shares be issued to it. 
 In connection with
this exercise, attached please find all documents required to be signed by the undersigned as per the terms of the Warrant, all duly executed by the undersigned and binding thereupon. 

 

			
	Name of Holder:	  	  

 
			
		
	Signature:	  	  

 
			
		
	Position of Signatory:	  	  

 
			
		
	Date:	  	  

  
 -8- 

 CDC-    A 

AMENDMENT TO 
 WARRANT TO
PURCHASE SHARES OF COMMON STOCK OF 
 AMEDICA CORPORATION 

This Amendment to Warrant to Purchase Shares of Common Stock (this “Amendment”) dated as of December ___ 2013,
is made by and between Amedica Corporation, a Delaware corporation (the “Company”), and the undersigned, ____________________ (the “Warrant Holder”), and it hereby amends that certain Warrant to
Purchase Shares of Common Stock of the Company originally issued as of [August 30/September 19], 2013 (the “Existing Warrant”), in connection with the Company’s offering of 100 units wherein each unit consisted of 50,000
shares of the Company’s Series F Convertible Preferred Stock and one five year warrant to acquire 25,000 shares of the Company’s common stock exercisable at $1.00 per share. 

NOW, THEREFORE, in consideration of the mutual promises contained herein, and the benefits to be derived by each party hereunder, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Warrant Holder, intending to be legally bound, hereby agree to amend the Existing Warrant, as set forth below and hereby agree as
follows: 
 AGREEMENT: 

Section 1. Amendment to Section 4 – Adjustments to Shares and Stated Purchase Price. Section 4 of the Existing Warrant is
hereby amended by inserting an additional paragraph immediately following Section 4(b) as follows: 
 “(c) If the
Company at any time after the date hereof through the Warrant Expiration Date issues or sells any stock or other security (other than warrants or options to subscribe for or purchase shares of Common Stock or Preferred Stock granted to employees or
consultants to the Company or securities issued by the Company in connection with an initial public offering of Common Stock) that is at any time and under any circumstances, directly or indirectly convertible into, exercisable or exchangeable for,
or which otherwise entitles the holder thereof to acquire any shares of Common Stock or Preferred Stock (the “Convertible Securities”), for a consideration per share less than the Stated Purchase Price then in effect or for which
the Convertible Securities have a conversion rate of less than the Stated Purchase Price then in effect, then the Stated Purchase Price in effect immediately prior to such issuance or sale will be reduced, concurrently with such issue, to the
consideration per share received by the Company for such issuance or sale. This Section 4(c) shall terminate and be of no further force or effect, and the Holder of the Warrant shall not be entitled to any adjustment in the Stated Purchase Price
upon and following the closing of an initial public offering of Common Stock.” 

 Section 2. No Further Amendments. Except as expressly amended hereby, the Existing Warrant
is in all respects ratified and confirmed and all the terms, conditions, and provisions thereof shall remain in full force and effect. 

Section 3. Effect of Amendment. This Amendment shall form a part of the Existing Warrant for all purposes, and each party thereto and
hereto shall be bound hereby. From and after the execution of this Amendment by the parties hereto, any reference to the Existing Warrant shall be deemed a reference to the Existing Warrant as amended hereby. 

Section 4. Headings. The descriptive headings contained in this Amendment are included for convenience of reference only and shall not
affect in any way the meaning or interpretation of this Amendment. 
 Section 5. Counterparts; Facsimiles. This Amendment may be
executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. A
facsimile or other electronically transmitted signature on this Amendment is as valid as an original signature. 
 Section 6. Governing
Law. This Amendment and the rights and duties of the parties hereto shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware. 

IN WITNESS WHEREOF, the Company and Warrant Holder have caused this Amendment to Warrant to Purchase Shares of Common Stock of Amedica
Corporation to be executed and delivered as of the date first written above by their respective officers thereunto duly authorized. 
  

									
	THE COMPANY:	 		 	WARRANT HOLDER:
			
	AMEDICA CORPORATION	 		 	[                    ]
					
	By:	 	 	 		 	By:	 	 
		 	 Name: Eric K. Olson
 Title:
  President and CEO
	 		 		 	 Print/Type Name:
 Print/Type
Title:EX-4.19

 Exhibit 4.19 

SERIES E 
 WARRANT
AGREEMENT 
 THIS SERIES E WARRANT AGREEMENT (this “Warrant Agreement”) dated April 7, 2010, is made by and
between ZIONS FIRST NATIONAL BANK, (“Zions”), and AMEDICA CORPORATION, a Delaware corporation (“Amedica”). Zions and Amedica are each referred to herein as a “Party” and collectively, the
“Parties.” 
 WHEREAS, the Parties have entered into an Amended and Restated Loan Agreement dated April 7, 2010 (the
“Loan Agreement”) which increases the maximum amount Amedica may borrow under its senior secured credit facility to up to $10,000,000, consisting of a $7,500,000 term loan and a $2,500,000 line of credit that may be increased
by $5,000,000 upon certain terms and conditions and lender’s subsequent approval; and 
 WHEREAS, the Loan Agreement provides that
Zions shall receive a warrant to purchase 50,000 shares of Series E Convertible Preferred Stock, par value $0.01 per share (the “Stock”); and 

WHEREAS, the Loan Agreement further provides that the warrant shall be issued pursuant to a definitive warrant agreement mutually agreed to by
Amedica and Zions. 
 NOW, THEREFORE, in consideration of the premises and the mutual agreements hereinafter set forth and for the purposes
of defining terms and provisions of the Warrant and the certificate representing the Warrant and the respective rights and obligations thereunder of Amedica, Zions and the holder of a certificate representing the Warrant, Amedica and Zions hereby
agree as follows: 
 Section 1. Form of Warrant. Amedica shall grant to Zions (Zions and/or its permitted assigns are
collectively referred to herein as the “Holder”) warrant(s) (the “Warrant”), in the form of Exhibit A hereto, to purchase shares of Stock at a purchase price of $2.20 per share (the
“Exercise Price”) all as more fully set forth herein. The Warrant shall be executed on behalf of Amedica by its Chief Financial Officer or any other authorized officer of Amedica, and dated as of the date of issuance of the
Warrant. 
 Section 2. Exercise Period of Warrant. The Warrant shall be exercisable at any time commencing on the first
anniversary of the date of issuance of the Warrant and shall terminate at 5:00 p.m., New York City Time, on April 7, 2015 (the “Warrant Termination Date’’); provided, however, that in the event of (a) the
closing of the issuance and sale of shares of the common stock, $0.01 par value per share (the “Common Stock”), of Amedica in Amedica’s first underwritten public offering (“IPO”) pursuant to an
effective registration statement under the Securities Act of 1933, as amended (the ‘‘Securities Act”) or (b) a Change of Control (as defined below), the Warrant shall, on the date of such event, become immediately
exercisable. 

 A “Change of Control” shall mean any acquisition of capital stock of
Amedica, directly or indirectly, any merger, tender offer, recapitalization or asset sale pursuant to which Amedica’s stockholders immediately prior to such transaction hold less than 50% of the voting securities of the surviving corporation
immediately after such transaction or the majority of the assets of Amedica are transferred or sold, except that any internal re-structuring or re-organization of Amedica that does not change the effective ultimate ownership of Amedica shall not be
deemed a Change of Control. 
 Section 3. Term of Warrant Agreement. Except as otherwise expressly provided herein, this
Warrant Agreement shall become void and all rights hereunder and all rights in respect thereof under the Warrant shall cease as of the Warrant Termination Date except to the extent that the Warrant is exercised prior to such date. 

Section 4. Number of Shares. The Warrant shall be exercisable for up to the number of shares of Stock determined in
accordance with the terms of the Loan Agreement, and such number shall be indicated on the Warrant, and which shall be subject to adjustment as provided herein (the “Warrant Shares”). 

Section 5. Adjustment Provisions. The Exercise Price and the number of shares of Stock underlying the Warrant shall be
subject to adjustment from time to time as hereinafter set forth: 
 (a) Stock Dividends – Stock Splits. If after the date
hereof, the number of outstanding shares of Stock is increased by a stock dividend payable in shares of Stock or by a sub-division or a stock split of shares of Stock or other similar event as described in the Certificate of Designation, Preferences
and Rights of the Stock, as amended from time to time (the “Certificate of Designation”), then, on the effective date thereof, the number of shares of Stock issuable on exercise of the Warrant shall be increased in proportion
to such increase in outstanding shares. 
 (b) Aggregation of Shares. If after the date hereof, the number of outstanding shares of
Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Stock or other similar event, then, on the effective date thereof, the number of shares of Stock issuable on exercise of the Warrant shall be
decreased in proportion to such decrease in outstanding shares. 
 (c) Adjustments in Exercise Price. Whenever the number of the
shares of Stock issuable upon the exercise of the Warrant is adjusted, as provided in Sections 5(a) and (b). the Exercise Price shall be adjusted (to the nearest cent) by multiplying such Exercise Price immediately prior to such adjustment by a
fraction (x) the numerator of which shall be the number of the shares of Stock purchasable upon the exercise of the Warrant immediately prior to such adjustment and (y) the denominator of which shall be the number of the shares of Stock so
purchasable immediately thereafter. 
 (d) When De Minimis Adjustment May Be Deferred. No adjustment in the Exercise Price need be
made unless the adjustment would require an increase or decrease of at least 1% in the Exercise Price. Any adjustments that are not made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this
Section 5 shall be made to the nearest 1/100th of a share. 

  
 - 2 - 

 (e) Notice. Whenever there shall be an adjustment as provided in this Section 5.
Amedica shall promptly cause written notice thereof to be sent to the Holder in accordance with Section 9 hereof, which notice shall be accompanied by an officer’s certificate setting forth the number of Warrant Shares purchasable upon the
exercise of the Warrant and the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment and the computation thereof. Additionally, in case at any time Amedica shall propose: 

(i) to pay any dividend or make any distribution on shares of Stock in shares of Stock or make any other distribution to all
holders of Stock; or 
 (ii) to issue any rights, warrants or other securities to all holders of Stock entitling them to
purchase any additional shares of Stock or any other rights, warrants or other securities; or 
 (iii) to effect any
reclassification or change of outstanding shares of Stock, or any consolidation, merger or sale; or 
 (iv) to effect any
liquidation, dissolution or winding-up of Amedica; 
 then, and in any one or more of such cases, Amedica shall give written notice thereof to the Holder in
accordance with Section 9 hereof, which notice shall be sent at least fifteen (15) days prior to (i) the date as of which the holders of record of shares of Stock to be entitled to receive any such dividend, distribution, rights,
warrants, other securities are to be determined or (ii) the date on which any such reclassification, change of outstanding shares of Stock, consolidation, merger, sale, liquidation, dissolution or winding-up is expected to become effective, and
the date as of which it is expected that holders of record of shares of Stock shall be entitled to exchange their shares for securities or other property, if any, deliverable upon such reclassification, change of outstanding shares, consolidation,
merger, sale, liquidation, dissolution or winding-up. 
 Section 6. Representations, Warranties and Covenants of Amedica.
Amedica hereby represents, warrants and covenants to Holder as follows: 
 (a) Amedica is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware and is in good standing as a foreign corporation in each jurisdiction in which the nature of its business makes such qualification necessary and where the failure to so qualify would have a
material adverse effect on its business or operations. Amedica has all requisite corporate power and authority to carry out its business as presently conducted and as proposed to be conducted and to enter into and discharge its obligations under
this Warrant Agreement and the Warrant. 
 (b) The execution and delivery of this Warrant Agreement and the Warrant by Amedica and its
performance and compliance with the terms of this Warrant Agreement and the Warrant have been duly authorized by all necessary corporate action on the part of Amedica. 

(c) The consummation of the transactions contemplated by this Warrant Agreement and the Warrant will not (i) conflict with, result in any
breach of any of the terms and provisions of, or constitute (with or without notice or lapse of time or both) a default under, the certificate of incorporation or bylaws of Amedica, or any material contract, agreement, indenture, loan agreement,
receivables purchase agreement, mortgage, deed of trust, or other 

  
 - 3 - 

 
agreement or instrument to which Amedica is a party or by which it or any of its properties is bound, (ii) result in the creation or imposition of any lien, adverse claim or other
encumbrance upon any of the properties of Amedica pursuant to the terms of any such material contract, agreement, indenture, loan agreement, receivables purchase agreement, mortgage, deed of trust, or other agreement or instrument, or
(iii) violate any law or order, rule or regulation applicable to Amedica of any court or of any federal or state regulatory body, administrative agency, or other governmental instrumentality having jurisdiction over Amedica or any of its
properties. 
 (d) This Warrant Agreement and the Warrant each constitutes a legal, valid and binding obligation of Amedica and each is
enforceable against Amedica in accordance with the terms hereof and thereof, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and
by general principles of equity (whether considered in a proceeding or action in equity or at law). 
 (e) Amedica shall at all times keep a
sufficient number of authorized but unissued shares of Stock reserved for issuance upon the exercise of the Warrant, and it also shall keep a sufficient number of authorized but unissued shares of Common Stock reserved for issuance upon conversion
any Warrant Shares that may be issued resulting from exercise of the Warrant. The Warrant Shares, when issued, delivered and paid for in accordance with the terms of this Warrant Agreement and the Warrant, will be duly and validly issued, fully paid
and nonassessable and will not have been issued in violation of the pre-emptive or contractual rights of any person or entity. 
 (f)
Amedica shall deliver to each Holder of ten percent (10%) or more of the aggregate Warrant Shares such information and reports relating to Amedica as Amedica is required to provide to other holders of the Stock. The rights of such Holders under
this Section 6(f) shall terminate upon the closing of the IPO. 
 (g) Upon receipt of evidence reasonably satisfactory to Amedica of
the loss, theft, destruction or mutilation of the Warrant or any certificate representing Warrant Shares, and, in the case of any such loss, theft or destruction, upon delivery of indemnity (which may include a bond) reasonably satisfactory to
Amedica, or, in the case of any such mutilation, upon surrender and cancellation of the Warrant or any certificate representing Warrant Shares, as the case may be. Amedica will issue a new Warrant or certificates representing Warrant Shares, as the
case may be, of like tenor representing an equivalent interest or right, in lieu of such lost, stolen, destroyed or mutilated Warrant or certificates representing Warrant Shares, as the case may be. The applicant for such replacement Warrant shall
comply with such other reasonable requests as Amedica may reasonably prescribe. 
 Section 7. Representations, Warranties and
Covenants of Holder. Holder hereby represents, warrants and covenants to Amedica as follows: 
 (a) Holder is acquiring the Warrant,
and upon exercise of the Warrant will acquire the Warrant Shares, for its own account with no intention of distributing or reselling the Warrant or Warrant Shares in any transaction that would be a violation of the securities laws of the United
States or any state, without prejudice to the Holder’s rights at all times to sell or otherwise dispose of all or part of such Warrant under a registration under the Securities Act or an exemption available thereto. Holder is aware that neither
the Warrant nor the Warrant Shares 

  
 - 4 - 

 
are registered under the Securities Act or any state or other jurisdiction’s securities laws, and that Holder must hold the Warrant and the Warrant Shares indefinitely unless subsequently
registered or an exemption from registration is available. Holder understands and agrees that the Warrant will bear the restrictive legend set forth on the Warrant and that the Warrant Shares will bear the legend set forth in Section 8 of this
Warrant Agreement. Holder represents and warrants that it is an “accredited investor” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. 

Section 8. Permitted Transfers and Exchanges. This Warrant Agreement and the Warrant are not transferable and may not be
assigned or otherwise transferred by the Holder, other than to Zions affiliates, subsidiaries and its parent company, without the prior written consent of Amedica. Amedica may from time to time register the transfer of the Warrant in a register to
be maintained by Amedica upon surrender thereof accompanied by a written instrument or instruments of transfer in the form of assignment attached hereto or as otherwise may be satisfactory to Amedica, duly executed by the Holder thereof or by the
duly appointed legal representative thereof or by a duly authorized attorney. Upon any such transfer, the surrendered Warrant shall be canceled and disposed of by Amedica and a new Warrant shall be issued to the transferee(s). The Holder agrees that
prior to any proposed transfer of the Warrant or of the Warrant Shares, if such transfer is not made pursuant to an effective registration statement under the Securities Act and any applicable state securities laws, the Holder shall deliver to
Amedica: 
 (a) an investment covenant substantially similar to Section 7(a) hereof and otherwise reasonably satisfactory to Amedica
signed by the proposed transferee; 
 (b) an agreement by such transferee to the impression of the restrictive investment legend set forth
below on the Warrant or the Warrant Shares; 
 (c) an agreement by such transferee that Amedica may place a notation in the stock books of
Amedica or a “stop transfer order” with any transfer agent or registrar with respect to the Warrant Shares; 
 (d) an agreement by
such transferee to be bound by the provisions of this Section 8 relating to the transfer of such Warrant or Warrant Shares; and 
 (e) an
opinion of counsel, reasonably satisfactory in form and substance to Amedica, that the transfer is exempt from registration requirements under the Securities Act and any applicable state securities laws. 

The Holder agrees that each Warrant and each certificate representing Warrant Shares will bear the following legend: 

THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS THE REGISTRATION PROVISIONS OF SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS HAVE BEEN COMPLIED WITH OR

  
 - 5 - 

 
UNLESS AMEDICA HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO AMEDICA THAT SUCH REGISTRATION IS NOT REQUIRED. 

Section 9. Notices. All demands, notices and communications relating to this Warrant Agreement or any Warrant shall be in
writing and (i) sent by registered or certified mail, postage prepaid, return receipt requested, (ii) hand delivered, (iii) sent by express mail or other reasonable overnight delivery service, or (iv) sent by telecopy, as
follows: 
  

			
	if to Amedica:	  	
	
	 Amedica Corporation
 1885 West 2100
South
 Salt Lake City, UT 84119

	Attention:	  	Reyn Gallacher
		  	Chief Financial Officer
	Telephone:	  	(801) 839-3500
	Telecopy:	  	(801) 839-3605
	
	with a copy to:
	
	 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center
 Boston, MA 02111

	Attention:	  	Jonathan L. Kravetz, Esq.
	Telephone:	  	(617) 542-6000
	Telecopy:	  	(617) 542-2241
		
	If to Holder:	  	
	
	 Zions First National Bank
 Corporate
Banking Division
 1 South Main, Suite 200
 Salt Lake City, Utah
84111

	Attention:	  	Thomas C. Etzel,
		  	Senior Vice President
	Telephone:	  	(801) 844-7122
	Telecopy:	  	(801) 594-8045
	
	with a copy to:
	
	John A. Beckstead
	Holland & Hart LLP
	222 South Main Street, Suite 2200
	Salt Lake City, UT 84101

 Any such demand, notice or communication hereunder shall be deemed to have been duly given when received by
the other party or parties at the address shown above or on the 

  
 - 6 - 

 
next succeeding business day if the date of receipt is not a business day, or such other address as may hereafter be furnished to the other party or parties by like notice and shall be deemed to
have been received on the date delivered to or received at the premises of the addresses. 
 Section 10. Counterparts.
For the purpose of facilitating the execution of this Warrant Agreement and for other purposes, this Warrant Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed to be an original, and all of which
together shall constitute and be one and the same instrument; and such counterparts may be delivered via facsimile to the numbers designated in or pursuant to Section 9 hereof. 

Section 11. Governing Law; Jurisdiction; Waiver of Jury Trial. 

(a) Governing Law. This Warrant Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware,
without regard to conflict of law principles. 
 (b) Jurisdiction. Each of Amedica and the Holder hereby irrevocably submits to the
jurisdiction of any New York State or Federal court sitting in New York City in any action or proceeding arising out of or relating to this Warrant Agreement or the Warrant, and each of Amedica and the Holder hereby irrevocably agrees that all
claims in respect of such action or proceeding may be heard and determined in such New York State court or in such Federal court. Each of Amedica and the Holder hereby irrevocably waives, to the fullest extent permitted under applicable law, the
defense of an inconvenient forum to the maintenance of such action or proceeding. Each of Amedica and the Holder irrevocably consents, to the fullest extent permitted under applicable law, to the service of any summons and complaint and any other
process by the mailing of copies of such process to them at their respective address specified in Section 9 hereof. Each of Amedica and the Holder hereby agrees, to the fullest extent permitted under applicable law, that a final judgment in any
such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

(c) Waiver of Jury Trial. TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE LAW, EACH OF AMEDICA AND THE HOLDER HEREBY IRREVOCABLY
WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS WARRANT AGREEMENT OR ANY WARRANT ISSUED HEREUNDER. 

Section 12. Amendments. This Warrant Agreement may be amended from time to time by written instrument signed by Amedica and
the Holders of a majority of the Warrant Shares issued or issuable upon exercise of the Warrant and no waiver of any of the terms hereof shall be effective unless it is in writing and signed by the Holders of a majority of the Warrant Shares issued
or issuable upon exercise of the Warrant or Amedica, as the case may be. Any amendment or waiver pursuant to this Section 12 shall be binding on all Holders of the Warrant Shares and may be given retroactive, prospective or concurrent effect,
depending upon the language in such amendment or waiver. 
 Section 13. No Waiver. No failure on the part of the Holder
or Amedica to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof; nor 

  
 - 7 - 

 
shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not
exclusive of any remedies provided by law. 
 Section 14. Termination. This Warrant Agreement shall terminate on the
Warrant Termination Date. Notwithstanding the foregoing, this Warrant Agreement will terminate on any earlier date if the Warrant has been exercised in full. 

  
 - 8 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Series E Warrant Agreement to be duly
executed by their respective officers on the day and year first above written. 
  

			
	AMEDICA CORPORATION
		
	By:	 	 /s/ Reyn Gallacher

	Name:	 	Reyn Gallacher
	Title:	 	Chief Financial Officer
	
	ZIONS FIRST NATIONAL BANK
		
	By:	 	 /s/ Thomas C. Etzel

	Name:	 	Thomas C. Etzel
	Title:	 	Senior Vice President

 Exhibit A 

THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS THE REGISTRATION PROVISIONS OF SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS HAVE BEEN COMPLIED WITH OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 Exercisable on or before 

the Warrant Termination Date 
 (as defined below)

 WARRANT TO PURCHASE SERIES E CONVERTIBLE PREFERRED STOCK 

To Subscribe for and Purchase Series E Convertible Preferred Stock 

of 
 AMEDICA CORPORATION

 WARRANT NO. E-16 
 This
certifies that, for value received, Zions First National Bank, (referred to herein as the “Holder”), is entitled to subscribe for and purchase from Amedica Corporation, a Delaware corporation (the
“Company”), at any time commencing on the first anniversary of the date hereof and shall terminate at 5:00 p.m., New York City Time, on the fifth anniversary of the date hereof (the “Warrant Termination
Date”), Fifty Thousand (50,000) shares (the “Warrant Shares”) of the Company’s Series E Convertible Preferred Stock, par value $0.01 per share (the “Series E Preferred Stock”),
subject to adjustment as provided in that certain Series E Warrant Agreement dated as of April 7, 2010, by and between the Company and Zions First National Bank (the “Warrant Agreement”), at an exercise price of $2.20
per share, as such exercise price may be adjusted from time to time under the Warrant Agreement. No Warrant may be exercised after the Warrant Termination Date. 

In the event of (a) the closing of the issuance and sale of shares of common stock. $0.01 par value per share (the “Common
Stock”) of the Company in the Company’s first underwritten public offering (“IPO”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), or (b) a Change of Control, the Warrant shall, on the date of such event, become immediately exercisable. 

  
 A-1 

 A “Change of Control” shall mean any acquisition of capital stock of the
Company, directly or indirectly, any merger, tender offer, recapitalization or asset sale pursuant to which the Company’s stockholders immediately prior to such transaction hold less than 50% of the voting securities of the surviving
corporation immediately after such transaction or the majority of the assets of the Company are transferred or sold, except that any internal restructuring or re-organization of the Company that does not change the effective ultimate ownership of
the Company shall not be deemed a Change of Control. 
 This Series E Convertible Preferred Stock Purchase Warrant and all Series E
Convertible Preferred Stock Purchase Warrants issued in substitution or exchange therefor are herein individually called a “Warrant” and collectively called “Warrants.” 

This Warrant is issued pursuant to and, subject to the terms and conditions of, the Warrant Agreement, which Warrant Agreement is incorporated
by reference in and made a part of this instrument. Capitalized terms not otherwise defined herein shall have the meanings given them in the Warrant Agreement. Any conflict between the terms of this Warrant and the Warrant Agreement shall be
resolved in favor of the terms of the Warrant Agreement. 
 This Warrant is further subject to the following provisions, terms and
conditions: 
 1. (a) In order to exercise this Warrant, in whole or in part, the Holder shall deliver to the Company, at the office the
Company designated for such purpose in Section 9 of the Warrant Agreement, (i) the form of election to purchase set forth herein properly completed and signed, (ii) payment of the Warrant Price pursuant to Section 1(b), and
(iii) this Warrant. Upon receipt of the items referred to in clauses (i), (ii) and (iii) above, the Company shall, as promptly as practicable, and in any event within ten (10) days thereafter, execute or cause to be executed and
deliver or cause to be delivered to the Holder a certificate or certificates, in such name or names as the Holder may designate, representing the aggregate number of full shares of Series E Convertible Preferred Stock issuable upon such exercise,
together with cash in lieu of any fraction of a share, as hereinafter provided in Section 4 hereof. If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased shares of Series E Convertible Preferred Stock called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant. 
 (b) Payment to the Company of the purchase price for the Warrant Shares so purchased (the
“Warrant Price”) may be made, at the option of the Holder, by payment of the Warrant Price in cash or by wire transfer or cashier’s check drawn on a United States bank. 

  
 A-2 

 (c) Net Exercise. In lieu of exercising this Warrant pursuant to Section 1(b), the
Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Series E Convertible Preferred Stock equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at
the principal office of the Company together with notice of such election, in which event the Company shall issue to the holder hereof a number of shares of Series E Convertible Preferred Stock computed using the following formula: 

 

							
		 	X =	 	 Y x (A–B)
	 	
		 		 	A	 	

  

					
	Where:	  	X =	  	The number of shares of Series E Convertible Preferred Stock to be issued to the Holder pursuant to this net exercise;
			
		  	Y =	  	The number of shares of Series E Convertible Preferred Stock in respect of which the net issue election is made;
			
		  	A =	  	The fair market value of one share of Series E Convertible Preferred Stock at the time the net issue election is made;
			
		  	B =	  	The Exercise Price (as adjusted to the date of the net issuance).

 For purposes of this Section 1(c), the fair market value of one share of Series E Convertible Preferred Stock (or
Common Stock, to the extent all such Series E Convertible Preferred Stock has been converted into the Company’s Common Stock) as of a particular date shall be determined as follows: (i) if traded on a securities exchange or through the
Nasdaq Global Market, the value shall be deemed to be the average of the closing prices of the securities on such exchange over the thirty (30) day period ending three (3) days prior to the net exercise election; (ii) if traded
over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty (30) day period ending three (3) days prior to the net exercise; and (iii) if there is no active
public market, the value shall be the fair market value thereof, as determined in good faith by the Board of Directors of the Company; provided, however, that, if the Warrant is being exercised upon the closing of an IPO, the value will be
the initial “Price to Public” of one share of such Series E Convertible Preferred Stock (or Common Stock issuable upon conversion of such Series E Convertible Preferred Stock) specified in the final prospectus with respect to such offering
(net of applicable underwriting commissions). 
 2. Notwithstanding the foregoing, however, the Company shall not be required to deliver any
certificate for shares of Series E Convertible Preferred Stock upon exercise of this Warrant except in accordance with the provisions, and subject to the limitations of, Section 4 hereof and the restrictive legend on the first page hereof.

 3. The Company covenants and agrees that the Warrant Shares will, upon issuance, delivery and receipt of consideration therefor, be duly
authorized and issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof. The Company further covenants and agrees that during the period within which the rights represented by this Warrant may
be exercised, the Company will at all times have authorized, and reserved for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant, a sufficient number of shares of Warrant Shares to provide for the
exercise of the rights represented by this Warrant, and it also will have authorized, and reserved for the purpose of issue, a sufficient number of shares of Common Stock to provide for the 

  
 A-3 

 
conversion of Warrant Shares. The Company will take all such action as may be necessary to assure that the Warrant Shares may be so issued without violation of any applicable law or regulation or
of any pre-emptive or contractual rights of any person or entity. 
 4. No fractional shares of Series E Convertible Preferred Stock shall
be issued upon the exercise of this Warrant, but, instead of any fraction of a share which would otherwise be issuable, the Company shall pay a cash adjustment in respect of such fraction in an amount equal to the same fraction of the fair market
value per share of Series E Convertible Preferred Stock as of the close of business on the date of the notice required by Section 1 above. 

5. This Warrant, unless and until exercised, shall not entitle the Holder to any voting rights or other rights as a stockholder of the
Company. 
 [SIGNATURE PAGE FOLLOWS] 

  
 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]